Document Detail


MDM2, MDMX and p53 in oncogenesis and cancer therapy.
MedLine Citation:
PMID:  23303139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumour suppressor. However, the MDM proteins modulate and respond to many other signalling networks in which they are embedded. Recent mechanistic studies and animal models have demonstrated how functional interactions in these networks are crucial for maintaining normal tissue homeostasis, and for determining responses to oncogenic and therapeutic challenges. This Review highlights the progress made and pitfalls encountered as the field continues to search for MDM-targeted antitumour agents.
Authors:
Mark Wade; Yao-Cheng Li; Geoffrey M Wahl
Related Documents :
23651199 - Cancer-induced immunosuppressive cascades and their reversal by molecular-targeted ther...
11193729 - Ii. vinzenz czerny (1842-1915): grand seigneur of oncologic surgery--life, influence, a...
23970479 - Mrna splicing variants: exploiting modularity to outwit cancer therapy.
24166959 - Deficiency of the myeloid differentiation primary response molecule myd88 leads to an e...
25109959 - Approaches for measuring signalling plasticity in the context of resistance to targeted...
25135429 - Molecular regulation of cervical cancer growth and invasion by vegfa.
8618999 - Periareolar mammaplasty: double skin technique with application of polyglactine or mixe...
21331359 - Tp53 mutations in nonsmall cell lung cancer.
19827339 - Evaluation of bone mass density on patients with prostate cancer prior to the start of ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-10
Journal Detail:
Title:  Nature reviews. Cancer     Volume:  13     ISSN:  1474-1768     ISO Abbreviation:  Nat. Rev. Cancer     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-24     Completed Date:  2013-03-17     Revised Date:  2014-09-12    
Medline Journal Info:
Nlm Unique ID:  101124168     Medline TA:  Nat Rev Cancer     Country:  England    
Other Details:
Languages:  eng     Pagination:  83-96     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cell Transformation, Neoplastic / genetics,  metabolism*
Humans
Neoplasms / genetics,  metabolism*,  therapy*
Proto-Oncogene Proteins c-mdm2 / genetics,  metabolism*
Tumor Suppressor Protein p53 / genetics,  metabolism*
Grant Support
ID/Acronym/Agency:
CA014195/CA/NCI NIH HHS; P30 CA014195/CA/NCI NIH HHS; R01 CA061449/CA/NCI NIH HHS; R01‑CA61449/CA/NCI NIH HHS; R03‑MH089489‑01/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/Tumor Suppressor Protein p53; EC 6.3.2.19/Proto-Oncogene Proteins c-mdm2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  LIM-domain-only proteins in cancer.
Next Document:  Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuva...